PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com/events-presentations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005239/en/
Members of PureTech’s management team will participate in fireside chats at the Piper Sandler 33rd Annual Virtual Healthcare Conference and Evercore ISI 4th Annual HealthCONx Conference on Monday, November 22, and Thursday, December 2, respectively. (Photo: Business Wire)
Piper Sandler 33rd Annual Virtual Healthcare Conference
Presenters: George Farmer, Ph.D., Chief Financial Officer; Michael Chen, Ph.D., Head of Innovation
Date: Fireside chat available as of 10:00 AM EST on Monday, November 22, 2021
Evercore ISI 4th Annual HealthCONx Conference
Presenters: Daphne Zohar, Founder and CEO; Michael Chen, Ph.D., Head of Innovation
Date: Thursday, December 2, 2021
Time: 11:45 AM EST
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 25 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Half Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact, including those related to our participation at upcoming investor conferences, should be considered forward-looking statements. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Allison Mead Talbot
+1 617 651 3156